BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75:976-981. [PMID: 19212416 DOI: 10.1038/ki.2009.21] [Cited by in Crossref: 196] [Cited by in F6Publishing: 176] [Article Influence: 15.1] [Reference Citation Analysis]
Number Citing Articles
1 Silverberg DS, Iaina A, Schwartz D, Wexler D. Intravenous Iron in Heart Failure: Beyond Targeting Anemia. Curr Heart Fail Rep 2011;8:14-21. [DOI: 10.1007/s11897-010-0034-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
2 Agarwal AK, Yee J. Hepcidin. Advances in Chronic Kidney Disease 2019;26:298-305. [DOI: 10.1053/j.ackd.2019.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Sihler KC, Raghavendran K, Westerman M, Ye W, Napolitano LM. Hepcidin in trauma: linking injury, inflammation, and anemia. J Trauma 2010;69:831-7. [PMID: 20938270 DOI: 10.1097/TA.0b013e3181f066d5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
4 Sam AH, Busbridge M, Amin A, Webber L, White D, Franks S, Martin NM, Sleeth M, Ismail NA, Daud NM, Papamargaritis D, Le Roux CW, Chapman RS, Frost G, Bloom SR, Murphy KG. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med 2013;30:1495-9. [PMID: 23796160 DOI: 10.1111/dme.12262] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
5 Asperti M, Denardo A, Gryzik M, Arosio P, Poli M. The role of heparin, heparanase and heparan sulfates in hepcidin regulation. Vitam Horm 2019;110:157-88. [PMID: 30798810 DOI: 10.1016/bs.vh.2019.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ibrahim IA, Mohamad UM, Darweesh HA, Rashad AM. Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients. Egypt J Intern Med 2014;26:6-14. [DOI: 10.4103/1110-7782.132882] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Cooke KS, Hinkle B, Salimi-moosavi H, Foltz I, King C, Rathanaswami P, Winters A, Steavenson S, Begley CG, Molineux G, Sasu BJ. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 2013;122:3054-61. [DOI: 10.1182/blood-2013-06-505792] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 7.6] [Reference Citation Analysis]
8 Grebenchtchikov N, Geurts-moespot AJ, Kroot JJC, den Heijer M, Tjalsma H, Swinkels DW, Sweep FGJ. High-sensitive radioimmunoassay for human serum hepcidin. British Journal of Haematology 2009;146:317-25. [DOI: 10.1111/j.1365-2141.2009.07758.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
9 Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010;73:527-36. [PMID: 19683083 DOI: 10.1016/j.jprot.2009.08.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
10 Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, Wharton J, Wilkins MR. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011;58:300-309. [PMID: 21737024 DOI: 10.1016/j.jacc.2011.02.057] [Cited by in Crossref: 140] [Cited by in F6Publishing: 137] [Article Influence: 12.7] [Reference Citation Analysis]
11 Pirojsakul K, Mathews N, Seikaly MG. Chronic Kidney Disease in Children: Recent Update. TOUNJ 2015;8:117-23. [DOI: 10.2174/1874303x015080100117] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
12 Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, Nossuli AK, Lepore JJ, Aarup M, Cobitz AR. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J 2019;12:139-48. [PMID: 30746141 DOI: 10.1093/ckj/sfy014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
13 Silverberg DS, Wexler D, Iaina A, Schwartz D. ANAEMIA MANAGEMENT IN CARDIO RENAL DISEASE: ANAEMIA MANAGEMENT IN CARDIO RENAL DISEASE. Journal of Renal Care 2010;36:86-96. [DOI: 10.1111/j.1755-6686.2010.00164.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
14 Silverberg DS, Wexler D, Iaina A, Schwartz D. Correction of iron deficiency in the cardiorenal syndrome. Int J Nephrol 2011;2011:365301. [PMID: 21603160 DOI: 10.4061/2011/365301] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
15 Caltabiano S, Cizman B, Burns O, Mahar KM, Johnson BM, Ramanjineyulu B, Serbest G, Cobitz AR. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin Kidney J 2019;12:693-701. [PMID: 31583094 DOI: 10.1093/ckj/sfz013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Gupta AK, David W. Does erythropoietin cause hemoglobin variability--is it 'normal'? PLoS One 2014;9:e92890. [PMID: 24709756 DOI: 10.1371/journal.pone.0092890] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Touzot M, Lefebvre T, Roux A, Maheas C, Ridel C, Puy H, Karim Z. Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients. Nephrology (Carlton) 2019;24:751-7. [PMID: 30175513 DOI: 10.1111/nep.13485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wish JB. Treatment of Anemia in Kidney Disease: Beyond Erythropoietin. Kidney Int Rep 2021;6:2540-53. [PMID: 34622095 DOI: 10.1016/j.ekir.2021.05.028] [Reference Citation Analysis]
19 Troutt JS, Rudling M, Persson L, Ståhle L, Angelin B, Butterfield AM, Schade AE, Cao G, Konrad RJ. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin Chem 2012;58:1225-32. [PMID: 22679180 DOI: 10.1373/clinchem.2012.186866] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
20 El Said HW, Abou Seif KH, Ahmed YS, Abou Elleil HA, El Said TW, Behairy MA, Mohamed MM, Ahmed FA. Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients. Nephrology (Carlton) 2018;23:323-30. [PMID: 28130911 DOI: 10.1111/nep.13010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Panwar B, Gutiérrez OM. Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease. Semin Nephrol 2016;36:252-61. [PMID: 27475656 DOI: 10.1016/j.semnephrol.2016.05.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
22 Rosati A, Ravaglia F, Panichi V. Improving Erythropoiesis Stimulating Agent Hyporesponsiveness in Hemodialysis Patients: The Role of Hepcidin and Hemodiafiltration Online. Blood Purif 2018;45:139-46. [PMID: 30959500 DOI: 10.1159/000485314] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
23 Li X, Chang J, Su Z, Li J, Peng B, Zhu S, Cai A, Zhang J, Jiang Y. How Does Short-Term Low-Dose Simvastatin Influence Serum Prohepcidin Levels in Patients With End-Stage Renal Disease? A Pilot Study: Simvastatin and Prohepcidin Levels in ESRD. Therapeutic Apheresis and Dialysis 2010;14:308-14. [DOI: 10.1111/j.1744-9987.2009.00783.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Akizawa T, Tanaka-amino K, Otsuka T, Yamaguchi Y. Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat. Clin Exp Nephrol. [DOI: 10.1007/s10157-022-02225-w] [Reference Citation Analysis]
25 Xu Y, Ding XQ, Zou JZ, Liu ZH, Jiang SH, Chen YM. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation. J Int Med Res 2011;39:1961-7. [PMID: 22118000 DOI: 10.1177/147323001103900542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
26 Chiu PF, Ko SY, Chang CC. Vitamin C affects the expression of hepcidin and erythropoietin receptor in HepG2 cells. J Ren Nutr 2012;22:373-6. [PMID: 22227182 DOI: 10.1053/j.jrn.2011.09.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
27 Belmouaz M, Bauwens M, Hauet T, Bossard V, Jamet P, Joly F, Chikhi E, Joffrion S, Gand E, Bridoux F. Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial. Nephrol Dial Transplant 2020;35:328-35. [PMID: 31578564 DOI: 10.1093/ndt/gfz189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
28 Wagner M, Ashby D. Hepcidin--a well-known iron biomarker with prognostic implications in chronic kidney disease. Nephrol Dial Transplant 2013;28:2936-9. [PMID: 24046195 DOI: 10.1093/ndt/gft330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
29 Sun CC, Vaja V, Chen S, Theurl I, Stepanek A, Brown DE, Cappellini MD, Weiss G, Hong CC, Lin HY, Babitt JL. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant 2013;28:1733-43. [PMID: 23345622 DOI: 10.1093/ndt/gfs584] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
30 Yılmaz I, Ozkok A, Kostek O, Kolukısa A, Duran I, Odabaş AR, Kemal Işman F, Işbilen Başok B. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients. Ren Fail 2016;38:89-95. [PMID: 26539647 DOI: 10.3109/0886022X.2015.1106896] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Srai SK, Chung B, Marks J, Pourvali K, Solanky N, Rapisarda C, Chaston TB, Hanif R, Unwin RJ, Debnam ES, Sharp PA. Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure. Kidney International 2010;78:660-7. [DOI: 10.1038/ki.2010.217] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
32 Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Ito K, Hanaki K, Wolf M, Hirakata H. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study. Sci Rep 2019;9:8877. [PMID: 31222044 DOI: 10.1038/s41598-019-45335-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
33 Morelle J, Labriola L, Jadoul M. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;76:1116; author reply 1116. [PMID: 19876058 DOI: 10.1038/ki.2009.334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Peters HP, Laarakkers CM, Pickkers P, Masereeuw R, Boerman OC, Eek A, Cornelissen EA, Swinkels DW, Wetzels JF. Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrol 2013;14:70. [PMID: 23531037 DOI: 10.1186/1471-2369-14-70] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
35 Wang K, Wu J, Xu J, Gu S, Li Q, Cao P, Li M, Zhang Y, Zeng F. Correction of Anemia in Chronic Kidney Disease With Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability. Front Pharmacol 2018;9:803. [PMID: 30108502 DOI: 10.3389/fphar.2018.00803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
36 Masajtis-Zagajewska A, Nowicki M. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease - a randomized double blind crossover study. Ren Fail 2018;40:700-9. [PMID: 30741616 DOI: 10.1080/0886022X.2018.1535983] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Hsieh YP, Huang CH, Lee CY, Chen HL, Lin CY, Chang CC. Hepcidin-25 negatively predicts left ventricular mass index in chronic kidney disease patients. World J Nephrol 2013; 2(2): 38-43 [PMID: 24175264 DOI: 10.5527/wjn.v2.i2.38] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
38 van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Gaillard CA, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012;7:e39783. [PMID: 22808058 DOI: 10.1371/journal.pone.0039783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
39 Nakanishi T, Hasuike Y, Otaki Y, Kida A, Nonoguchi H, Kuragano T. Hepcidin: another culprit for complications in patients with chronic kidney disease? Nephrology Dialysis Transplantation 2011;26:3092-100. [DOI: 10.1093/ndt/gfr410] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
40 El Sewefy DA, Farweez BA, Behairy MA, Yassin NR. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients. Int Urol Nephrol 2019;51:325-34. [DOI: 10.1007/s11255-018-2062-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Daher R, Ducrot N, Lefebvre T, Zineeddine S, Ausseil J, Puy H, Karim Z. Crosstalk between Acidosis and Iron Metabolism: Data from In Vivo Studies. Metabolites 2022;12:89. [DOI: 10.3390/metabo12020089] [Reference Citation Analysis]
42 Beaumont C, Karim Z. Actualité du métabolisme du fer. La Revue de Médecine Interne 2013;34:17-25. [DOI: 10.1016/j.revmed.2012.04.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
43 Vallet N, Delaye JB, Ropert M, Foucault A, Ravalet N, Deriaz S, Chalopin T, Blasco H, Maillot F, Hérault O, Gyan E. Megaloblastic anemia-related iron overload and erythroid regulators: a case report. J Med Case Rep 2021;15:463. [PMID: 34538261 DOI: 10.1186/s13256-021-03065-0] [Reference Citation Analysis]
44 Rochette L, Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C. The iron-regulatory hormone hepcidin: A possible therapeutic target? Pharmacology & Therapeutics 2015;146:35-52. [DOI: 10.1016/j.pharmthera.2014.09.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
45 Kakimoto-shino M, Toya Y, Kuji T, Fujikawa T, Umemura S. Changes in Hepcidin and Reticulocyte Hemoglobin Equivalent Levels in Response to Continuous Erythropoietin Receptor Activator Administration in Hemodialysis Patients: A Randomized Study: Hepcidin Response in CERA Treatment. Ther Apher Dial 2014;18:421-6. [DOI: 10.1111/1744-9987.12161] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
46 Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. PLoS One 2016;11:e0157063. [PMID: 27276035 DOI: 10.1371/journal.pone.0157063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
47 Drakou A, Margeli A, Theodorakopoulou S, Agrogiannis I, Poziopoulos C, Papassotiriou I, Vlahakos DV. Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose. Blood Cells Mol Dis 2016;59:100-5. [PMID: 27282576 DOI: 10.1016/j.bcmd.2016.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
48 Mole DR. Iron Homeostasis and Its Interaction with Prolyl Hydroxylases. Antioxidants & Redox Signaling 2010;12:445-58. [DOI: 10.1089/ars.2009.2790] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
49 Malyszko J, Malyszko JS. Emerging drugs for the treatment of kidney disease-induced anemia. Expert Opin Emerg Drugs 2016;21:315-30. [PMID: 27537859 DOI: 10.1080/14728214.2016.1220537] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
50 Stefánsson BV, Abramson M, Nilsson U, Haraldsson B. Hemodiafiltration improves plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. Nephron Extra 2012;2:55-65. [PMID: 22619668 DOI: 10.1159/000336482] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
51 Gharekhani A, Khatami MR, Dashti-Khavidaki S, Razeghi E, Abdollahi A, Hashemi-Nazari SS, Mansournia MA. Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. Daru 2014;22:11. [PMID: 24397938 DOI: 10.1186/2008-2231-22-11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
52 Chand S, Ward DG, Ng ZY, Hodson J, Kirby H, Steele P, Rooplal I, Bantugon F, Iqbal T, Tselepis C, Drayson MT, Whitelegg A, Chowrimootoo M, Borrows R. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J Nephrol 2015;28:81-8. [PMID: 24687402 DOI: 10.1007/s40620-014-0083-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
53 Lee SW, Kim JM, Lim HJ, Hwang YH, Kim SW, Chung W, Oh KH, Ahn C, Lee KB, Sung SA. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance. Sci Rep 2017;7:4260. [PMID: 28652624 DOI: 10.1038/s41598-017-04664-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
54 Šimetić L, Zibar L. Laboratory use of hepcidin in renal transplant recipients. Biochem Med (Zagreb) 2016;26:34-52. [PMID: 26981017 DOI: 10.11613/BM.2016.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013;98:1667-76. [PMID: 24186312 DOI: 10.3324/haematol.2013.084624] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
56 den Elzen WP, de Craen AJ, Wiegerinck ET, Westendorp RG, Swinkels DW, Gussekloo J. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica 2013;98:448-54. [PMID: 23065507 DOI: 10.3324/haematol.2012.068825] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
57 Robach P, Recalcati S, Girelli D, Campostrini N, Kempf T, Wollert KC, Corbella M, Santambrogio P, Perbellini L, Brasse-Lagnel C, Christensen B, Moutereau S, Lundby C, Cairo G. Serum hepcidin levels and muscle iron proteins in humans injected with low- or high-dose erythropoietin. Eur J Haematol 2013;91:74-84. [PMID: 23582009 DOI: 10.1111/ejh.12122] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
58 Peters HP, Rumjon A, Bansal SS, Laarakkers CM, van den Brand JA, Sarafidis P, Musto R, Malyszko J, Swinkels DW, Wetzels JF, Macdougall IC. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrology Dialysis Transplantation 2012;27:3923-9. [DOI: 10.1093/ndt/gfs164] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
59 Guidi GC, Lechi Santonastaso C. Advancements in anemias related to chronic conditions. Clin Chem Lab Med 2010;48:1217-26. [PMID: 20618092 DOI: 10.1515/CCLM.2010.264] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
60 Chand SK, Singh RG, Pendharkar SA, Bharmal SH, Petrov MS. Interplay between innate immunity and iron metabolism after acute pancreatitis. Cytokine 2018;103:90-8. [PMID: 28982582 DOI: 10.1016/j.cyto.2017.09.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
61 Larson DS, Coyne DW. Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease. Kidney Res Clin Pract 2013;32:11-5. [PMID: 26894030 DOI: 10.1016/j.krcp.2013.01.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
62 Bârsan L, Stanciu A, Stancu S, Căpuşă C, Brătescu L, Mandache E, Radu E, Mircescu G. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia. Hematology 2015;20:543-52. [PMID: 25745821 DOI: 10.1179/1607845415Y.0000000004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
63 Kawamura T, Usui J, Kaneko S, Tsunoda R, Imai E, Kai H, Morito N, Saito C, Nagata M, Yamagata K. Anaemia is an essential complication of ANCA-associated renal vasculitis: a single center cohort study. BMC Nephrol 2017;18:337. [PMID: 29178888 DOI: 10.1186/s12882-017-0754-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
64 Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, Martinelli N, Lupo A, Olivieri O, Girelli D. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol. 2010;2010:329646. [PMID: 20414466 DOI: 10.1155/2010/329646] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
65 Bansal SS, Abbate V, Bomford A, Halket JM, Macdougall IC, Thein SL, Hider RC. Quantitation of hepcidin in serum using ultra-high-pressure liquid chromatography and a linear ion trap mass spectrometer. Rapid Commun Mass Spectrom 2010;24:1251-9. [PMID: 20391595 DOI: 10.1002/rcm.4512] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
66 Vela D. Systemic and local hepcidin as emerging and important peptides in renal homeostasis and pathology. Biofactors 2019;45:118-34. [PMID: 30461080 DOI: 10.1002/biof.1468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol 2020;16:77-98. [PMID: 31554933 DOI: 10.1038/s41581-019-0197-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
68 Hanudel MR, Czaya B, Wong S, Rappaport M, Namjoshi S, Chua K, Jung G, Gabayan V, Qiao B, Nemeth E, Ganz T. Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin. Kidney Int 2021:S0085-2538(21)01077-2. [PMID: 34838540 DOI: 10.1016/j.kint.2021.10.036] [Reference Citation Analysis]
69 Goyal H, Mohanty S, Sharma M, Rani A. Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin. Indian J Nephrol 2017;27:44-50. [PMID: 28182038 DOI: 10.4103/0971-4065.179301] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
70 Macdougall IC, Bircher AJ, Eckardt K, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM, Adamson JW, Akizawa T, Anker SD, Auerbach M, Bárány P, Besarab A, Bhandari S, Cabantchik I, Collins AJ, Coyne DW, de Francisco ÁL, Fishbane S, Gaillard CA, Ganz T, Goldsmith DJ, Hershko C, Jankowska EA, Johansen KL, Kalantar-zadeh K, Kalra PA, Kasiske BL, Locatelli F, Małyszko J, Mayer G, Mcmahon LP, Mikhail A, Nemeth E, Pai AB, Parfrey PS, Pecoits-filho R, Roger SD, Rostoker G, Rottembourg J, Singh AK, Slotki I, Spinowitz BS, Tarng D, Tentori F, Toblli JE, Tsukamoto Y, Vaziri ND, Winkelmayer WC, Wheeler DC, Zakharova E. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International 2016;89:28-39. [DOI: 10.1016/j.kint.2015.10.002] [Cited by in Crossref: 144] [Cited by in F6Publishing: 143] [Article Influence: 24.0] [Reference Citation Analysis]
71 Yousaf F, Spinowitz B. Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin? Curr Hypertens Rep 2016;18. [DOI: 10.1007/s11906-016-0629-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
72 Cui Y, Wu Q, Zhou Y. Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int 2009;76:1137-41. [PMID: 19776721 DOI: 10.1038/ki.2009.357] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
73 Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant 2015;30:187-96. [PMID: 24821751 DOI: 10.1093/ndt/gfu104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
74 Atkinson MA, Kim JY, Roy CN, Warady BA, White CT, Furth SL. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr Nephrol 2015;30:635-43. [PMID: 25380788 DOI: 10.1007/s00467-014-2991-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
75 Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011;57:1650-1669. [PMID: 21989113 DOI: 10.1373/clinchem.2009.140053] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 13.9] [Reference Citation Analysis]
76 Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current Status of the Measurement of Blood Hepcidin Levels in Chronic Kidney Disease: Table 1. CJASN 2010;5:1681-9. [DOI: 10.2215/cjn.05990809] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
77 Tomasz G, Ewa W, Jolanta M. Biomarkers of iron metabolism in chronic kidney disease. Int Urol Nephrol 2021;53:935-44. [PMID: 33025407 DOI: 10.1007/s11255-020-02663-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Zaritsky JJ, Young BY. The utility of multivariate analysis in the study of hepcidin. Kidney International 2009;76:912. [DOI: 10.1038/ki.2009.272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
79 Valenti L, Messa P, Pelusi S, Campostrini N, Girelli D. Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clin Chem Lab Med 2014;52:613-9. [PMID: 24231125 DOI: 10.1515/cclm-2013-0769] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
80 Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 2010;5:1010-4. [PMID: 20299375 DOI: 10.2215/CJN.08161109] [Cited by in Crossref: 62] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
81 Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009;4:1384-7. [PMID: 19556376 DOI: 10.2215/CJN.02190309] [Cited by in Crossref: 70] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
82 Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 2010;78:769-73. [PMID: 20668427 DOI: 10.1038/ki.2010.254] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
83 Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M. Renal anemia of inflammation: the name is self-explanatory. Blood Purif 2011;32:220-5. [PMID: 21829013 DOI: 10.1159/000328037] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
84 Haase VH, Chertow GM, Block GA, Pergola PE, deGoma EM, Khawaja Z, Sharma A, Maroni BJ, McCullough PA. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant 2019;34:90-9. [PMID: 29672740 DOI: 10.1093/ndt/gfy055] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
85 Malyszko J, Malyszko JS, Mysliwiec M. Hyporesponsiveness to Erythropoietin Therapy in Hemodialyzed Patients: Potential Role of Prohepcidin, Hepcidin, and Inflammation. Renal Failure 2009;31:544-8. [DOI: 10.1080/08860220903082606] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
86 Zaman BA, Rasool SO, Ibrahim NMR, Abdulah DM. HeGRI: A Novel Index of Serum Hepcidin Suppression in Relation to the Degree of Renal Dysfunction among β-Thalassemia Major Patients. Thalassemia Reports 2022;12:2-11. [DOI: 10.3390/thalassrep12010002] [Reference Citation Analysis]
87 Mansion F, Chiap P, Houbart V, Crommen J, Servais A, Fillet M. Optimization of micro-HPLC peak focusing for the detection and quantification of low hepcidin concentrations. J Sep Science 2011;34:1820-7. [DOI: 10.1002/jssc.201100244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
88 Haase-fielitz A, Plaß M, Kuppe H, Hetzer R, Ostland V, Westphal S, Hoffmann J, Prowle J, Mertens PR, Westerman M, Bellomo R, Haase M. Low preoperative hepcidin concentration as a risk factor for mortality after cardiac surgery: A pilot study. The Journal of Thoracic and Cardiovascular Surgery 2013;145:1380-6. [DOI: 10.1016/j.jtcvs.2012.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
89 Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631-1634. [PMID: 22935483 DOI: 10.1681/asn.2011111078] [Cited by in Crossref: 352] [Cited by in F6Publishing: 194] [Article Influence: 35.2] [Reference Citation Analysis]
90 Peters HP, Laarakkers CM, Wetzels JF, Swinkels DW. Hepcidin levels in patients with renal disease. Kidney Int. 2009;76:680; author reply 680-681. [PMID: 19721430 DOI: 10.1038/ki.2009.238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
91 Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease: Pentoxifylline and haemoglobin. Nephrology 2010;15:344-9. [DOI: 10.1111/j.1440-1797.2009.01203.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
92 Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 2019;23:407-21. [PMID: 30907175 DOI: 10.1080/14728222.2019.1599358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
93 Eguchi A, Mochizuki T, Tsukada M, Kataoka K, Hamaguchi Y, Oguni S, Nitta K, Tsuchiya K. Serum hepcidin levels and reticulocyte hemoglobin concentrations as indicators of the iron status of peritoneal dialysis patients. Int J Nephrol 2012;2012:239476. [PMID: 23193472 DOI: 10.1155/2012/239476] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
94 Altman NL, Patel A. Intravenous Iron Therapy in Heart Failure. Heart Fail Clin 2018;14:537-43. [PMID: 30266362 DOI: 10.1016/j.hfc.2018.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, Okada N, Yamamoto R, Nagasawa Y, Kato K, Isaka Y, Rakugi H, Tsubakihara Y. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant 2012;27:1076-83. [PMID: 21799206 DOI: 10.1093/ndt/gfr431] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
96 Chan W, G. Ward D, Mcclean A, A. Bosch J, Jones D, Kaur O, Drayson M, Whitelegg A, Iqbal T, Mcternan PG, Tselepis C, Borrows R. The Role of Hepcidin-25 in Kidney Transplantation. Transplantation 2013;95:1390-5. [DOI: 10.1097/tp.0b013e31828d8489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
97 Volke M, Gale DP, Maegdefrau U, Schley G, Klanke B, Bosserhoff AK, Maxwell PH, Eckardt KU, Warnecke C. Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PLoS One 2009;4:e7875. [PMID: 19924283 DOI: 10.1371/journal.pone.0007875] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 4.8] [Reference Citation Analysis]
98 Cohen G. Immune Dysfunction in Uremia 2020. Toxins (Basel) 2020;12:E439. [PMID: 32635646 DOI: 10.3390/toxins12070439] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
99 Ali TM, Genina AM, Abo-salem OM. The determinants of hepcidin level in chronic kidney disease and hemodialysis Saudi patients. Beni-Suef University Journal of Basic and Applied Sciences 2014;3:133-9. [DOI: 10.1016/j.bjbas.2014.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
100 Haraguchi K, Uto H, Ohnou N, Tokunaga M, Tokunaga M, Utsunomiya A, Hanada S, Tsubouchi H. Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma. Exp Ther Med 2012;4:581-8. [PMID: 23170109 DOI: 10.3892/etm.2012.663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
101 Laller S, Patel S, Haldar D. Role of Serum and Urinary Hepcidin in Young Females of Reproductive Age in North India. J Lab Physicians. [DOI: 10.1055/s-0041-1735585] [Reference Citation Analysis]
102 Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol. 2013;88:97-101. [PMID: 23335357 DOI: 10.1002/ajh.23354] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 11.2] [Reference Citation Analysis]
103 Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrology Dialysis Transplantation 2010;25:848-53. [DOI: 10.1093/ndt/gfp546] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 5.2] [Reference Citation Analysis]
104 Sasaki Y, Noguchi-sasaki M, Matsuo-tezuka Y, Matsumoto-omori Y, Kurasawa M, Yorozu K, Shimonaka Y. Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice. Int J Hematol 2014;99:561-9. [DOI: 10.1007/s12185-014-1554-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
105 Md Yusop AH, Ulum MF, Al Sakkaf A, Hartanto D, Nur H. Insight into the bioabsorption of Fe-based materials and their current developments in bone applications. Biotechnol J 2021;:e2100255. [PMID: 34520117 DOI: 10.1002/biot.202100255] [Reference Citation Analysis]
106 Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant. 2012;27:709-715. [PMID: 21617198 DOI: 10.1093/ndt/gfr288] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
107 Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol. 2009;46:387-393. [PMID: 19786207 DOI: 10.1053/j.seminhematol.2009.06.001] [Cited by in Crossref: 189] [Cited by in F6Publishing: 166] [Article Influence: 14.5] [Reference Citation Analysis]
108 Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. Kidney Int Suppl (2011) 2021;11:46-58. [PMID: 33777495 DOI: 10.1016/j.kisu.2020.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
109 Itkonen O, Parkkinen J, Stenman UH, Hämäläinen E. Preanalytical factors and reference intervals for serum hepcidin LC-MS/MS method. Clin Chim Acta 2012;413:696-701. [PMID: 22222553 DOI: 10.1016/j.cca.2011.12.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
110 McKnight Q, Jenkins S, Li X, Nelson T, Marlier A, Cantley LG, Finberg KE, Fretz JA. IL-1β Drives Production of FGF-23 at the Onset of Chronic Kidney Disease in Mice. J Bone Miner Res 2020;35:1352-62. [PMID: 32154933 DOI: 10.1002/jbmr.4003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
111 Miseta A, Nagy J, Nagy T, Poór VS, Fekete Z, Sipos K. Hepcidin and its potential clinical utility. Cell Biol Int 2015;39:1191-202. [PMID: 26109250 DOI: 10.1002/cbin.10505] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
112 Brătescu LO, Bârsan L, Gârneaţă L, Stanciu A, Lipan M, Stancu SH, Mircescu G. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency. Int Urol Nephrol 2014;46:1005-12. [PMID: 24800994 DOI: 10.1007/s11255-014-0696-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
113 Deira J, González-sanchidrián S, Polanco S, Cebrián C, Jiménez M, Marín J, Gómez-martino J, Fernández-pereira L, Tabernero J. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients. Renal Failure 2016;38:1076-81. [DOI: 10.1080/0886022x.2016.1184937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
114 Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Gauci C, Froissart M, Stengel B; NephroTest Study Group. A 3-marker index improves the identification of iron disorders in CKD anaemia. PLoS One 2014;9:e84144. [PMID: 24586229 DOI: 10.1371/journal.pone.0084144] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
115 Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol 2016;27:1234-44. [PMID: 26494831 DOI: 10.1681/ASN.2014111139] [Cited by in Crossref: 100] [Cited by in F6Publishing: 47] [Article Influence: 14.3] [Reference Citation Analysis]
116 Touzot M, Lefebvre T, Maheas C, Ridel C, Puy H, Karim Z. A hepcidin-based approach for iron therapy in hemodialysis patients: A pilot study. Hemodial Int 2020;24:188-94. [PMID: 32048444 DOI: 10.1111/hdi.12823] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Poggiali E, Migone De Amicis M, Motta I. Anemia of chronic disease: A unique defect of iron recycling for many different chronic diseases. European Journal of Internal Medicine 2014;25:12-7. [DOI: 10.1016/j.ejim.2013.07.011] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
118 Tsuchiya K, Nitta K. Hepcidin is a Potential Regulator of Iron Status in Chronic Kidney Disease: Hepcidin and Anemia in Dialysis. Therapeutic Apheresis and Dialysis 2013;17:1-8. [DOI: 10.1111/1744-9987.12001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
119 Panwar B, McCann D, Olbina G, Westerman M, Gutiérrez OM. Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial. BMC Nephrol 2018;19:35. [PMID: 29426300 DOI: 10.1186/s12882-018-0823-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
120 Chen MX, Kuehne N, Mattman A, Liu J, Van der Gugten G, Wright B. Clinical interpretation of serum hepcidin-25 in inflammation and renal dysfunction. Journal of Mass Spectrometry and Advances in the Clinical Lab 2022;24:43-9. [DOI: 10.1016/j.jmsacl.2022.03.002] [Reference Citation Analysis]
121 Moulouel B, Houamel D, Delaby C, Tchernitchko D, Vaulont S, Letteron P, Thibaudeau O, Puy H, Gouya L, Beaumont C, Karim Z. Hepcidin regulates intrarenal iron handling at the distal nephron. Kidney Int. 2013;84:756-766. [PMID: 23615502 DOI: 10.1038/ki.2013.142] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
122 Zeigler BM, Vajdos J, Qin W, Loverro L, Niss K. A mouse model for an erythropoietin-deficiency anemia. Dis Model Mech 2010;3:763-72. [PMID: 20959632 DOI: 10.1242/dmm.004788] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
123 Kroot JJ, Laarakkers CM, Geurts-moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HP, van Dongen-lases E, Wetzels JF, Sweep FC, Tjalsma H, Swinkels DW. Immunochemical and Mass-Spectrometry–Based Serum Hepcidin Assays for Iron Metabolism Disorders. Clinical Chemistry 2010;56:1570-9. [DOI: 10.1373/clinchem.2010.149187] [Cited by in Crossref: 142] [Cited by in F6Publishing: 146] [Article Influence: 11.8] [Reference Citation Analysis]
124 Chang C, Chiu P, Chen H, Chang T, Chang Y, Huang C. Simvastatin downregulates the expression of hepcidin and erythropoietin in HepG2 cells: Simvastatin downregulates hepcidin. Hemodial Int 2013;17:116-21. [DOI: 10.1111/j.1542-4758.2012.00716.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
125 Zhong Z, Luo D, Luo N, Li B, Fu D, Fan L, Li Z, Chen W, Mao H. Serum Hepcidin-25 and Risk of Mortality in Patients on Peritoneal Dialysis. Front Med (Lausanne) 2021;8:684548. [PMID: 34222290 DOI: 10.3389/fmed.2021.684548] [Reference Citation Analysis]
126 Cohen G, Haag-Weber M, Hörl WH. Immune dysfunction in uremia. Kidney Int Suppl. 1997;62:S79-S82. [PMID: 23202302 DOI: 10.3390/toxins4110962] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 3.1] [Reference Citation Analysis]
127 Brătescu LO, Bârsan L, Munteanu D, Stancu S, Mircescu G. Is Hepcidin-25 a Clinically Relevant Parameter for the Iron Status in Hemodialysis Patients? Journal of Renal Nutrition 2010;20:S77-83. [DOI: 10.1053/j.jrn.2010.06.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
128 Atkinson MA, White CT. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 2012;27:33-40. [PMID: 21400189 DOI: 10.1007/s00467-011-1832-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
129 Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis 2017;69:815-26. [PMID: 28242135 DOI: 10.1053/j.ajkd.2016.12.011] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
130 Schuemann K, Solomons NW, Laarakkers CM, Romero-abal M, Kroll S, Weiss G, Swinkels DW. Reproducibility of and Correspondence among Different Hepcidin Forms in Blood and Urine and Their Relationships to Iron Status in Healthy, Male Guatemalan Volunteers Observed over 9 Weeks. Ann Nutr Metab 2011;58:158-66. [DOI: 10.1159/000328657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
131 Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrology Dialysis Transplantation 2010;25:3996-4002. [DOI: 10.1093/ndt/gfq321] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
132 Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-4433. [PMID: 21346250 DOI: 10.1182/blood-2011-01-258467] [Cited by in Crossref: 563] [Cited by in F6Publishing: 510] [Article Influence: 51.2] [Reference Citation Analysis]
133 Schwarz P, Strnad P, von Figura G, Janetzko A, Krayenbühl P, Adler G, Kulaksiz H. A novel monoclonal antibody immunoassay for the detection of human serum hepcidin. J Gastroenterol 2011;46:648-56. [DOI: 10.1007/s00535-010-0344-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
134 Fievet P, Coppin M, Brazier F, Lefèvre M, Stephan R, Demontis R. Traitement de la carence martiale en prédialyse par l’administration intraveineuse de doses élevées de fer dextran de bas poids moléculaire. Néphrologie & Thérapeutique 2012;8:41-6. [DOI: 10.1016/j.nephro.2011.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
135 Malyszko J. Hepcidin Assays: Ironing Out Some Details. CJASN 2009;4:1015-6. [DOI: 10.2215/cjn.02690409] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
136 Sedlackova T, Racek J, Rajdl D, Kielberger L, Eiselt J, Malanova L, Babuska V. Relationship between hepcidin and ferritin in haemodialysed patients. Wien Klin Wochenschr 2013;125:448-52. [DOI: 10.1007/s00508-013-0388-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
137 Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1051-1056. [PMID: 19406957 DOI: 10.2215/cjn.05931108] [Cited by in Crossref: 200] [Cited by in F6Publishing: 97] [Article Influence: 15.4] [Reference Citation Analysis]
138 Savković M, Simić-Ogrizović S, Dopsaj V. Factors associated with hepcidin-25 levels in maintenance hemodialysis patients. Ther Apher Dial 2021;25:565-74. [PMID: 33403761 DOI: 10.1111/1744-9987.13617] [Reference Citation Analysis]
139 Petrulienė K, Žiginskienė E, Kuzminskis V, Nedzelskienė I, Bumblytė IA. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Medicina (Kaunas) 2017;53:90-100. [PMID: 28416170 DOI: 10.1016/j.medici.2017.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
140 Price EA, Schrier SL. Unexplained aspects of anemia of inflammation. Adv Hematol 2010;2010:508739. [PMID: 20368776 DOI: 10.1155/2010/508739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
141 Hanudel MR, Wong S, Jung G, Qiao B, Gabayan V, Zuk A, Ganz T. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone. Kidney Int 2021;100:79-89. [PMID: 33811979 DOI: 10.1016/j.kint.2021.03.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
142 Nakanishi T, Kuragano T, Nanami M, Nagasawa Y, Hasuike Y. Misdistribution of iron and oxidative stress in chronic kidney disease. Free Radic Biol Med 2019;133:248-53. [PMID: 29958932 DOI: 10.1016/j.freeradbiomed.2018.06.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
143 van Eijk LT, Kroot JJ, Tromp M, van der Hoeven JG, Swinkels DW, Pickkers P. Inflammation-induced hepcidin-25 is associated with the development of anemia in septic patients: an observational study. Crit Care 2011;15:R9. [PMID: 21219610 DOI: 10.1186/cc9408] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
144 Holdstock L, Cizman B, Meadowcroft AM, Biswas N, Johnson BM, Jones D, Kim SG, Zeig S, Lepore JJ, Cobitz AR. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J 2019;12:129-38. [PMID: 30746140 DOI: 10.1093/ckj/sfy013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
145 van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013;28:3062-71. [PMID: 23147161 DOI: 10.1093/ndt/gfs488] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
146 Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87:392-400. [PMID: 22290531 DOI: 10.1002/ajh.23110] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 11.4] [Reference Citation Analysis]
147 Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014;29:263-73. [PMID: 24235084 DOI: 10.1093/ndt/gft443] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
148 Meléndez-Flores JD, Estrada-Bellmann I. Linking chronic kidney disease and Parkinson's disease: a literature review. Metab Brain Dis 2021;36:1-12. [PMID: 32990929 DOI: 10.1007/s11011-020-00623-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Anoshkina Y, Costas-Rodríguez M, Speeckaert M, Van Biesen W, Delanghe J, Vanhaecke F. Iron isotopic composition of blood serum in anemia of chronic kidney disease. Metallomics 2017;9:517-24. [PMID: 28417130 DOI: 10.1039/c7mt00021a] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
150 Ashby DR, Gale DP, Busbridge M, Maxwell PH, Choi P. Response to ‘Hepcidin levels in patients with renal disease’. Kidney International 2009;76:680-1. [DOI: 10.1038/ki.2009.240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Takata T, Chikumi H, Morishita S, Hamada S, Hoi S, Iyama T, Fukui T, Matono T, Fukuda S, Munemura C, Isomoto H. Shewanella algae Bacteremia in an End-stage Renal Disease Patient: A Case Report and Review of the Literature. Intern Med 2017;56:729-32. [PMID: 28321079 DOI: 10.2169/internalmedicine.56.7616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
152 Yilmaz H, Cakmak M, Darcin T, Inan O, Bilgic MA, Bavbek N, Akcay A. Can Serum Gdf-15 be Associated with Functional Iron Deficiency in Hemodialysis Patients? Indian J Hematol Blood Transfus 2016;32:221-7. [PMID: 27065587 DOI: 10.1007/s12288-015-0551-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
153 Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010;55:726-741. [PMID: 20189278 DOI: 10.1053/j.ajkd.2009.12.030] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 11.0] [Reference Citation Analysis]
154 Anderson DS, Kirchner M, Kellogg M, Kalish LA, Jeong J, Vanasse G, Berliner N, Fleming MD, Steen H. Design and Validation of a High-Throughput Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry Method for Quantification of Hepcidin in Human Plasma. Anal Chem 2011;83:8357-62. [DOI: 10.1021/ac2020905] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
155 Nalado AM, Olorunfemi G, Dix-Peek T, Dickens C, Khambule L, Snyman T, Paget G, Mahlangu J, Duarte R, George J, Naicker S. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol 2020;21:415. [PMID: 32993549 DOI: 10.1186/s12882-020-02046-7] [Reference Citation Analysis]
156 Chand SK, Singh RG, Pendharkar SA, Petrov MS. Iron: a Strong Element in the Pathogenesis of Chronic Hyperglycaemia After Acute Pancreatitis. Biol Trace Elem Res 2018;183:71-9. [PMID: 28836100 DOI: 10.1007/s12011-017-1131-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
157 Hamada Y, Fukagawa M. Is hepcidin the star player in iron metabolism in chronic kidney disease? Kidney International 2009;75:873-4. [DOI: 10.1038/ki.2009.46] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
158 Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney International 2011;80:240-4. [DOI: 10.1038/ki.2011.141] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
159 Wagner M, Ashby DR, Kurtz C, Alam A, Busbridge M, Raff U, Zimmermann J, Heuschmann PU, Wanner C, Schramm L. Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease. PLoS One 2015;10:e0123072. [PMID: 25894587 DOI: 10.1371/journal.pone.0123072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
160 van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010;12:943-50. [PMID: 20601671 DOI: 10.1093/eurjhf/hfq099] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 4.6] [Reference Citation Analysis]
161 Limm-Chan B, Wesseling-Perry K, Pearl MH, Jung G, Tsai-Chambers E, Weng PL, Hanudel MR. Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients. Pediatr Nephrol 2021. [PMID: 33903951 DOI: 10.1007/s00467-021-05081-0] [Reference Citation Analysis]
162 Panichi V, Scatena A, Rosati A, Giusti R, Ferro G, Malagnino E, Capitanini A, Piluso A, Conti P, Bernabini G, Migliori M, Caiani D, Tetta C, Casani A, Betti G, Pizzarelli F. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrology Dialysis Transplantation 2015;30:682-9. [DOI: 10.1093/ndt/gfu345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
163 Niikura T, Maruyama Y, Nakashima S, Matsuo N, Tanno Y, Ohkido I, Yokoyama K, Yamamoto H, Yokoo T. Hepcidin/Ferritin Ratios Differ Among Non-Dialyzed Chronic Kidney Disease Patients, and Patients on Hemodialysis and Peritoneal Dialysis. Ther Apher Dial 2019;23:341-6. [PMID: 30411489 DOI: 10.1111/1744-9987.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Sasu BJ, Li H, Rose MJ, Arvedson TL, Doellgast G, Molineux G. Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Blood Cells Mol Dis 2010;45:238-45. [PMID: 20800515 DOI: 10.1016/j.bcmd.2010.07.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
165 Xu P, Wong RSM, Krzyzanski W, Yan X. Dynamics of Erythroferrone Response to Erythropoietin in Rats. Front Pharmacol 2022;13:876573. [DOI: 10.3389/fphar.2022.876573] [Reference Citation Analysis]
166 Butterfield AM, Luan P, Witcher DR, Manetta J, Murphy AT, Wroblewski VJ, Konrad RJ. A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 2010;56:1725-32. [PMID: 20847326 DOI: 10.1373/clinchem.2010.151522] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
167 Memoli B, Salerno S, Procino A, Postiglione L, Morelli S, Sirico ML, Giordano F, Ricciardone M, Drioli E, Andreucci VE, Bartoli LD. A translational approach to micro-inflammation in end-stage renal disease: molecular effects of low levels of interleukin-6. Clin Sci (Lond) 2010;119:163-74. [PMID: 20380647 DOI: 10.1042/CS20090634] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
168 Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol 2016;311:F1369-77. [PMID: 27733366 DOI: 10.1152/ajprenal.00281.2016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
169 Goyal J, McCleskey B, Adamski J. Peering into the future: hepcidin testing. Am J Hematol 2013;88:976-8. [PMID: 23798368 DOI: 10.1002/ajh.23519] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
170 Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B; NephroTest Study Group. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 2014;9:e99781. [PMID: 24978810 DOI: 10.1371/journal.pone.0099781] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
171 Sasaki Y, Shimonaka Y, Ikuta K, Hosoki T, Sasaki K, Torimoto Y, Kanada H, Moriguchi Y, Kohgo Y. Hepcidin production in response to iron is controlled by monocyte-derived humoral factors. Int J Hematol 2014;99:12-20. [PMID: 24293278 DOI: 10.1007/s12185-013-1476-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
172 Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int 2017;21 Suppl 1:S21-7. [PMID: 28328097 DOI: 10.1111/hdi.12556] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
173 Patel V, Joharapurkar A, Kshirsagar S, Patel M, Patel H, Savsani H, Jain M. Hepcidin inhibition improves iron homeostasis in ferrous sulfate and LPS treatment model in mice. Drug Res (Stuttg) 2021. [PMID: 34311475 DOI: 10.1055/a-1542-8531] [Reference Citation Analysis]
174 Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JC, Swinkels DW. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009;94:1748-52. [PMID: 19996119 DOI: 10.3324/haematol.2009.010322] [Cited by in Crossref: 126] [Cited by in F6Publishing: 120] [Article Influence: 10.5] [Reference Citation Analysis]
175 Takasawa K, Tomosugi N, Takaeda C, Maeda T, Ueda N. Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients. Nephron Extra 2014;4:55-63. [PMID: 24847351 DOI: 10.1159/000362212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
176 Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JF, Kiemeney LA, Sweep FC, den Heijer M, Swinkels DW. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117:e218-e225. [PMID: 21527524 DOI: 10.1182/blood-2011-02-337907] [Cited by in Crossref: 178] [Cited by in F6Publishing: 172] [Article Influence: 16.2] [Reference Citation Analysis]
177 Cheng PP, Jiao XY, Wang XH, Lin JH, Cai YM. Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia.Clin Exp Med. 2011;11:33-42. [PMID: 20499129 DOI: 10.1007/s10238-010-0102-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
178 Vilela EM, Bastos JA, Fernandes N, Ferreira AP, Chaoubah A, Bastos MG. Treatment of chronic periodontitis decreases serum prohepcidin levels in patients with chronic kidney disease. Clinics (Sao Paulo) 2011;66:657-62. [PMID: 21655762 DOI: 10.1590/s1807-59322011000400022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
179 Troutt JS, Butterfield AM, Konrad RJ. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Anal 2013;27:504-10. [PMID: 24218134 DOI: 10.1002/jcla.21634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
180 Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010;2010:750643. [PMID: 20066043 DOI: 10.1155/2010/750643] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
181 Kato A. Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio–renal anemia syndrome. Future Cardiology 2010;6:769-71. [DOI: 10.2217/fca.10.97] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
182 Sasaki Y, Noguchi-Sasaki M, Yasuno H, Yorozu K, Shimonaka Y. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol 2012;96:692-700. [PMID: 23160767 DOI: 10.1007/s12185-012-1217-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
183 Kuragano T, Furuta M, Shimonaka Y, Kida A, Yahiro M, Otaki Y, Hasuike Y, Matsumoto A, Nakanishi T. The removal of serum hepcidin by different dialysis membranes. Int J Artif Organs 2013;36:633-9. [PMID: 23918276 DOI: 10.5301/ijao.5000221] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
184 Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, Bernhardt T. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease. Nephron 2019;143:243-54. [PMID: 31387097 DOI: 10.1159/000502012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
185 Maxwell PH, Eckardt K. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol 2016;12:157-68. [DOI: 10.1038/nrneph.2015.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 20.9] [Reference Citation Analysis]
186 Antunes SA, Vilela RQ, Vaz JD, Canziani ME. Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis. Int J Artif Organs 2014;37:521-8. [PMID: 25044383 DOI: 10.5301/ijao.5000340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
187 Vela D, Leshoski J, Vela Z, Jakupaj M, Mladenov M, Sopi RB. Insulin treatment corrects hepcidin but not YKL-40 levels in persons with type 2 diabetes mellitus matched by body mass index, waist-to-height ratio, C-reactive protein and Creatinine. BMC Endocr Disord 2017;17:53. [PMID: 28841871 DOI: 10.1186/s12902-017-0204-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
188 Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman R, Maxwell PH, Choi P. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010;95:505-8. [PMID: 19833632 DOI: 10.3324/haematol.2009.013136] [Cited by in Crossref: 119] [Cited by in F6Publishing: 118] [Article Influence: 9.2] [Reference Citation Analysis]